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Genetics of SCID
Fausto Cossu
Abstract
Human SCID (Severe Combined Immunodeficiency) is a prenatal disorder of T lymphocyte development, that
depends on the expression of numerous genes. The knowledge of the genetic basis of SCID is essential for diag-
nosis (e.g., clinical phenotype, lymphocyte profile) and treatment (e.g., use and type of pre-hematopoietic stem cell
transplant conditioning).
Over the last years novel genetic defects causing SCID have been discovered, and the molecular and immunologi-
cal mechanisms of SCID have been better characterized. Distinct forms of SCID show both common and peculiar
(e.g., absence or presence of nonimmunological features) aspects, and they are currently classified into six groups
according to prevalent pathophysiological mechanisms: impaired cytokine-mediated signaling; pre-T cell receptor
defects; increased lymphocyte apoptosis; defects in thymus embryogenesis; impaired calcium flux; other
mechanisms.
This review is the updated, extended and largely modified translation of the article “Cossu F: Le basi genetiche
delle SCID“, originally published in Italian language in the journal “Prospettive in Pediatria“ 2009, 156:228-238.
Introduction
The initial clinical manifestations of SCID (Severe Com-
bined Immunodeficiency), a heterogeneous group of
genetic defects with an overall incidence of about 1 in
40,000 to 75,000 newborns [1-3], are most frequently
observed in the first few months of life and the median
age at diagnosis is 4-7 months. However, human SCID
is a prenatal disorder of T lymphocyte development,
already present at birth even if clinically silent in most
affected newborns.
On January 1, 2008, Wisconsin (USA) became the
first state in the world to screen all newborns for SCID
through a method based on measurement of T cell
receptor excision circles (TRECs) by polymerase chain
reaction (PCR), using DNA extracted from newborn
dried blood spots (Guthrie cards); TRECs are by-
products generated during normal T cell maturation
(Figure 1) and are consistently absent or present in very
low numbers in newborns with SCID [4]. Recently an
infant with SCID has been identified by newborn
screening in Massachusetts [5], and the U.S. Depart-
ment of Health and Human Services recommended the
addition of SCID to the uniform screening panel for all
newborns [6].
Wisconsin SCID screening poster (Figure 2) describes
the fundamental features of SCID: children with SCID
do not produce T lymphocytes (or, however, functional
T lymphocytes), acquire multiple, persistent and severe
viral, bacterial and fungal infections shortly after birth,
fail to thrive, and rarely reach their first birthday; SCID
is a pediatric emergency [7]: with prompt diagnosis and
treatment and before acquiring an infection, including
infections from “live” vaccines (e.g., Bacille Calmette-
Guérin, and recently rotavirus) [8,9], essentially every
baby with SCID could be cured by hematopoietic stem
cell transplantation (HSCT)o rgene therapy (GT).
It is very useful to remember other general aspects of
SCID:
￿ Most newborns with SCID appear normal and
healthy at birth; slight cutaneous signs similar to
GvHD (Graft versus Host Disease) from engraftment
of transplacentally derived maternal T lymphocytes
are sometimes present. Instead, low birth length and
weight, microcephaly, dysmorphic facies, metaphy-
seal chondrodysplasia or other skeletal abnormalities,
alopecia, congenital heart disease, etc. are nonimmu-
nological manifestations of the less frequent forms
of SCID in which cell types and organs other than
lymphocytes and lymphoid organs are also affected
by their genetic mutations (Table 1).
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appear normal at birth, SCID is always a prenatal
disorder of the development of T lymphocytes and it
is already present at birth. In fact, the newborn
screening through TRECs does neither measure
enzyme activity nor search for mutations: it only
counts normal naïve T lymphocytes, already absent
or markedly reduced. Note that unlike mice (in
Figure 1 T cell Receptor Excision Circles (TRECs). TRECs are episomal DNA circles produced in thymocytes by excisional rearrangements of
T cell receptor (TCR) genes; they are stable, not duplicated during mitosis, diluted out with each cell division, and therefore higher in
thymocytes, recent thymic emigrants (RTEs) and naïve T cells. Quantitative polymerase chain reaction (PCR) of coding-joint (cj) δRec ψJa TREC,
produced at TCRa/δ locus within chromosome 14 (14q11) by >70% of developing human a:b T cells, counts in the peripheral blood naïve a:b T
lymphocytes recently dismetted by thymus: in newborn, values <25 TRECs/μL indicate SCID.
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Abstract
Severe combined immunodeficiency (SCID)--also known as “Bubble Boy Disease”--is 
a group of genetic defects causing blocks in T-cell development, hence causing 
immune deficiency.  SCID babies acquire severe, persistent, recurrent infections 
shortly after birth, fail to thrive, and rarely reach their first birthday.  With prompt 
diagnosis and treatment before infections, including infections from attenuated 
vaccines, they can be cured by bone marrow transplant.     
We have developed a newborn screening test for SCID based on  measurement of T-
cell receptor excision circles (TRECs) by real-time qPCR using DNA extracted from 
newborn screening dried blood spots (DBS).  TRECs are by-products generated 
during T-cell maturation and are consistently absent or present in low numbers in 
newborns with SCID.
Through a collaboration of Wisconsin Division of Public Health, Wisconsin State 
Laboratory of Hygiene, Children’s Hospital of Wisconsin and Jeffrey Modell
Foundation, SCID screening was implemented for all Wisconsin-born infants on 
January 1, 2008.  This pilot study will continue for 2-3 years with the CDC funding 
($500K per year) starting October 1, 2008.
Objectives
Develop a robust SCID screening laboratory protocol, establish a SCID screening 
algorithm, and demonstrate that SCID screening can be integrated into NBS 
programs.
Methods
The screening method is based on the absolute measurement of TRECs by real-time 
qPCR using DNA extracted from 3.2 mm NBS dried blood spots. The copy number of 
TRECs and β-actin were automatically determined based the standard curve (Figure 
1).  There are three reporting categories of results and follow up recommendations: 
normal screening reports, no action taken; inconclusive screening reports, second 
NBS requested (retesting); and abnormal screening reports, confirmatory test (flow 
cytometry)  and consultation with immunologists recommended on full term newborns 
(gestation ≥ 37 weeks), and tracking  the subsequent re-screening results of premature 
newborns (gestation ≤ 36 weeks).
Real-time qPCR to Measure TRECs
SCID Screening Reporting Algorithm
TREC ุ25/µl TREC <25 Re-test card for TREC 
& β-Actin
TREC <25 /µl &
low β−actin
INCONCLUSIVE report;
request new card
NORMAL
TRECs <25 &
normal ˟-actin
Notify PCP:
Confer with
Clinical Immunology
Consultants
TREC <25 & 
Normal or Low β−actin
Premature/NICU infant
TREC Analysis
ABNORMAL REPORT
SCID Screening Results
Screening Confirmation Results
Conclusions
We optimized the method of measuring TRECs by real-time qPCR to screen for SCID, 
which is amenable to NBS throughput.  We established screening protocols for testing, 
reporting and follow-up.  Our preliminary experience indicates that screening all 
newborns for SCID is feasible and results in an acceptable rate of screening false 
positives.  Quantitating the number of TRECs (markers for naïve T-cells) on newborn 
dry blood spots identifies infants with a variety of primary immunodeficiencies.
Figure 1. Example of real-time qPCR analysis for TRECs on DNA samples from 
DBS.  A) Arrows indicate serially diluted plasmid standards.  B) A standard curve of 
serially diluted plasmids containing a known copy number of TRECs (solid squares) 
and unknown DBS samples (crosses).   One of the plasmid standards (100 TRECs) 
is embedded in the unknown DBS samples. 
Figure 2 Wisconsin Newborn SCID screening poster. Reproduced with kind permission of the WI State Laboratory of Hygiene,
http://www.slh.wisc.edu/posters/Baker102808.pdf.
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Prevalent mechanisms/Disease T/B/NK Gene Locus Heredity Protein
§§ Nonimmunological manifestations
Impaired cytokine-mediated signaling
Common g chain defect T
-B
+NK
- IL2RG Xq13.1 XL Common g chain
JAK3 defect T
-B
+NK
- JAK3 19p13.1 AR Janus kinase 3
IL-7Ra chain defect T
-B
+NK
+ IL7RA 5p13 AR IL-7 and TSLP
receptor a chain
Defects of the pre-T cell receptor
Defects in V(D)J recombination
RAG1 defect T
-B
-NK
+ RAG1 11p13 AR RAG1
RAG2 defect T
-B
-NK
+ RAG2 11p13 AR RAG2
Artemis defect T
-B
-NK
+ DCLRE1C 10p13 AR Artemis radiosensitivity
DNA-PKcs defect T
-B
-NK
+ PRKDC 8q11.21 AR DNA-PKcs radiosensitivity
DNA ligasi IV defect T
-B
-NK
+ LIG4 13q33.3 AR DNA ligasi IV radiosensitivity, dysmorphic facies,
microcephaly, growth
retardation, psychomotor delay
Cernunnos/XLF defect T
-B
-NK
+ NHEJ1 2q35 AR Cernunnos/XLF radiosensitivity, dysmorphic facies,
microcephaly, growth
retardation, psychomotor delay
Impaired signaling through the pre-T
cell receptor
CD3δ defect T
-B
+NK
+ CD3D 11q23 AR CD3δ
CD3ε defect T
-B
+NK
+ CD3E 11q23 AR CD3ε
CD3ζ defect T
-B
+NK
+ CD3Z 1q24.2 AR CD3ζ
CD3g defect T
-B
+NK
+ CD3G 11q23 AR CD3g
CD45 T
-B
+NK
-/
+
PTPRC 1q31.3 AR CD45 (LCA)
ZAP-70 defect T
+B
+NK
+ ZAP70 2q11.2 AR ZAP-70
CD4
+
CD8
-
p56lck defect T
-B
+NK
+ LCK 1p35.1 AR p56lck
Increased lymphocyte apoptosis
Reticular dysgenesis T
-B
-NK
- AK2 1p34 AR Adenylate kinase
2
aleukocytosis, sensorineural deafness
ADA-SCID T
-B
-NK
- ADA 20q13.11 AR Adenosine
deaminase
costochondral and skeletal alterations,
neonatal hepatitis, sensorineural deafness,
neurological problems
PNP-SCID T
-B
-NK
- PNP 14q11.2 AR Purine
nucleoside
phosphorylase
neurological problems
Defects in thymus embryogenesis
Nude/SCID Syndrome T
-B
+NK
+ WHN 17q11.2 AR FOXN1 alopecia; embryonic neural tube defects
Complete DiGeorge Anomaly
DiGeorge Syndrome (del22q11.2) T
-B
+NK
+ >3 5
genes
22q11.2 AD TBX1, and others dysmorphic facies, congenital heart disease
and other
malformations, neonatal hypocalcemia by
absence of
parathyroid glands
CHARGE T
-B
+NK
+ CHD7 8q12.1 AD CHD-7 CHARGE association (coloboma, heart
defects, atresia
choanae, retardated growth and
development, genital
hypoplasia, ear anomalies/deafness)
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causes SCID) normal development of the human
immune system starts very early and it is notably
advanced before birth: in absence of SCID, in
human embryos (since 9-10 weeks of age) there is
intensive thymic T lymphopoiesis; and human in
u t e r oe x p o s u r et of o r e i g nantigens does activate
immunological response and does not produce toler-
ance, apart that toward noninherited maternal
alloantigens (tolerance mediated by specific regula-
tors T lymphocytes CD4
+CD25
highFoxP3
+ TReg,t h a t
represent 15-20% of CD4
+ T lymphocytes in the per-
ipheral lymphoid organs of the human fetus) [10].
Therefore, in utero HSCT had success (also if
usually partial: graft of T cells but not B cells) in
human SCID fetuses, but failed completely - 0% suc-
cessful (!!) with moreover 24% “procedure-related
death” - in 17/17 fetuses with hemoglobinopathies
(thalassemia, sickle cell disease) and normal immune
system [11].
￿ The development and function of Tl y m p h o c y t e s
are severely compromised in all forms of SCID
("congenital severe T cell immunodeficiencies”);
however, T lymphocytes, B lymphocytes and NK
(natural killer) lymphocytes (note that NK cells,
unlike T and B lymphocytes, do not rearrange their
germline DNA to produce genes encoding antigen-
specific receptors) share progenitors for cell lineages,
signaling pathways in development and function,
and metabolic pathways. Therefore, also B lympho-
cytes and/or NK cells are usually severely compro-
m i s e di nS C I D , and the distinct forms of SCID are
characterized by different combinations of T/B/NK
counts: T
-B
-NK
-,T
-B
+NK
-,T
-B
-NK
+ ,T
-B
+NK
+
(
- means absence or severely reduced counts). More-
over, without normal CD4
+ T helper lymphocytes
(TH1, TH2, TReg,T FH,T H17, TH22, TH9) [12,13], B
lymphocytes (in SCID agammaglobulinemia is the
rule, with rare exceptions), macrophages and also
eventual residual T lymphocytes cannot work even if
present and “normal”.
￿ In most SCID the absence of T lymphocytes causes
marked lymphopenia, with often an absolute lym-
phocyte count (ALC) < 500 cells/μL. Note that in
adults lymphopenia means ALC < 1,000/μL, but the
normal lower limits are 2,000/μLi nn e w b o r n sa n d
4,000/μL in infants by 6 to 9 months of age; there-
fore, in the first few months of life any ALC <
2,500/μL is potentially pathogenic and may indicate
SCID [14].
￿ However, many infants with SCID have T cells,
showing slightly reduced, normal (T
+ SCID)o rh i g h
Table 1 Classification of SCID (Continued)
Diabetic mother embryopathy T
-B
+NK
+ congenital heart disease, gut and kidney
malformations,
neural tube defects, sacral agenesis,
holoprosencephaly,
neonatal hypoglycemia
Impaired calcium flux
ORAI1 defect T
+B
+NK
+ ORAI1 12q24 AR ORAI1 myopathy, ectodermal dysplasia
STIM1 defect T
+B
+NK
+ STIM1 11p15.5 AR STIM1 myopathy, ectodermal dysplasia
Other mechanisms
Coronin-1A defect T
-B
+NK
+ CORO1A 16p11.2 AR Coronin-1A
MHC Class II defect T
+B
+NK
+ CIITA 16p13.13 AR CIITA
CD4
-
CD8
+
RFXANK 19p13.11 AR RFXANK
RFX5 1q21.2 AR RFX5
RFXAP 13q13.3 AR RFXAP
CHH (Cartilage hair hypoplasia) T
-B
+NK
+ RMRP 9p13.3 AR
§§ RNA of
RNase MRP
complex
short-limbed dwarfism, light-colored
hypoplastic hair
Hoyeraal-Hreidarsson Syndrome (HHS) T
+B
-NK
- DKC1 Xq28 XL Dyskerin cerebellar hypoplasia, microcephaly, growth
retardation,
bone marrow failure, hypoplastic hair
TERT 5p15.33 AR TERT
TINF2 14q12 AD TIN2
DCLRE1B 1p13.2 AD Apollo
Hereditary folate malabsorption (HFM) T
+B
+NK
+ SLC46A1 17q11.2 AR PCFT megaloblastic anemia, seizures, risk of
severe
neurodevelopmental defects
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++ SCID) T cell counts: e.g., “functional” T
+B
+
NK
+ SCID in the defects of calcium channels [15], T
+ (CD4
+CD8
-)B
+NK
+ SCID in the defect of ZAP70
[16], T
+B
-NK
- SCID in the Hoyeraal-Hreidarsson
syndrome [17].
But, T
+ or T
++ SCID are most frequently due to
abnormal and oligoclonal T cells that modify counts
from T
-B
-NK
- to T
+B
-NK
-,f r o mT
-B
+NK
- to T
+B
+NK
-,f r o mT
-B
-NK
+ to T
+B
-NK
+,o rf r o mT
-B
+NK
+
to T
+B
+NK
+. Such abnormal T lymphocytes (oligo-
clonal Vb TCR families; very low naïve CD4
+CD45RA
+ T cells; high memory CD4
+CD45RO
+ T
cells; high activated CD3DR
+ T cells; very low/absent
in vitro mitogen-induced lymphocyte proliferation;
and, very low/absent TRECs, that is very important
regard to newborn SCID screening) are present in
two main conditions:
1) SCID with massive engraftment of transplacen-
tally derived maternal T lymphocytes: such mater-
nal T lymphocytes are very useful for the diagnosis
of SCID (HLA typing of infant’s peripheral blood;
maternal DNA in infant’s peripheral blood), and may
also cause various and unusual manifestations: skin
and liver GvHD [18], autoimmune thrombocytope-
nia or pancytopenia (pre- or post-HSCT), rejection
of HSCT from father or donors other than mother
[19], monoclonal gammopathy because of clonal
expansion of maternal or newborn B cells in absence
of normal CD4
+TReg lymphocytes (Figure 3) [20],
attenuated clinical SCID if fetus/mother HLA com-
patibility [21].
2) Omenn Syndrome: caused by hypomorphic
mutations ("leaky SCID”) not only of rag1-rag2
(recombination activating gene 1-2) [22] but also of
almost all other genes whose null mutations cause
instead typical SCID (Figure 4) [16,23-32]. Clinically,
Omenn syndrome is not a “leaky” SCID and has a
poor prognosis; it is an extremely serious T
+ or T
++
SCID with pathogenic child’s( n o tm a t e r n a l )autolo-
gous oligoclonal hyper-autoreactive CD4
+ TH2l y m -
phocytes, produced because of non-null mutations
and then expanded by lack of central and peripheral
immunological tolerance (respectively: thymic defect
of thymocyte-dependent epithelial and dendritic cells
and of AIRE, Autoimmune Regulator Element,
expression; and defect of CD4
+TReg lymphocytes)
Figure 3 Monoclonal IgG gammopathy in a Sardinian 4-month-old female infant.A RT
-B
-NK
+SCID, modified to T
++B
-NK
+ SCID by massive
maternal T lymphocyte engraftment; ALC 16,740/μL, IgG 3,390 mg/dL; homozygous frameshift > nonsense mutation of DCLRE1C gene (Artemis
defect).
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tening infections typical of SCID, Omenn infants
present with aggressive tissue inflammation, very
severe erythroderma (absent at birth), protein loss
through the skin and the gut, unmanageable diar-
rhea, generalized edema, metabolic alterations, raised
serum IgE, hypereosinophilia, alopecia and loss of
eyebrows and eyelashes, enlarged lymph nodes and
epatosplenomegaly; usually, signs and symptoms do
not appear simultaneously and evolve with time [23].
￿ Therefore, mutations of the same gene can cause
both typical SCID and Omenn syndrome but also
various atypical clinical pictures and moreover slight
immunological defects with later manifestations in
adult age [36,37]. The variability of the clinical phe-
notypes is a common aspect of the genetic defects
causing SCID [38], and it is observed also in siblings
with the same mutation (interference of other
genetic factors, environmental factors, etc.) [39,40].
In certain cases, clinical phenotypes are attenuated
because of somatic mosaicism by spontaneous
genetic reversion (correction of the mutation) in a
somatic cellular line that then expands itself [41].
Genotypes and clinical aspects of SCID
With the exception of the complete DiGeorge anomaly
and some cases of the Hoyeraal-Hreidarsson syndrome
(autosomal dominant, AD), all forms of SCID are auto-
somal recessive (AR-SCID) or X-linked recessive (XL-
SCID) monogenic disorders.
An updated classification of SCID is based on underly-
ing genetics and prevalent molecular pathogenetic
mechanisms (Table 1).
SCID caused by impaired cytokine-mediated signaling
Common gamma chain (gc) defect (OMIM, Online
Mendelian Inheritance in Man, 300400)
Only male infants are affected by common gamma chain
(gc) defect, XL T
-B
+NK
-SCID caused by mutations of
IL2RG gene, localized at Xq13.1 and encoding the g
chain (gc) of interleukin-2 (IL-2) receptor. David Vetter
(Figure 5; Figure 6) was affected by this SCID (his muta-
tion: IL2RG nonsense exon 7 C937A S308X, -62 aa. of
369 aa.) [42-45]; the “bubble boy paradox” (IL-2 defi-
cient knockout mice and the rare IL-2 deficient human
patients do not have SCID but instead severe defect of
CD4
+ TReg lymphocytes and autoimmunity) was
resolved by the discovery that IL-2 receptor g chain is
shared (common g chain) by the receptors of IL-4, IL-7,
IL-9, IL-15, and IL-21; IL-7 and IL-15 are essential for
the development of T lymphocytes and NK cells, respec-
tively [46,47].
At least in the United States, this XL-SCID ("X-SCID”)
is the most frequent SCID; it is an exclusively immuno-
logical form except that also cutaneous keratinocytes
express gc-dependent cytokine receptors and the asso-
ciated JAK3 (see later), and these is necessary for the
local innate immunity of keratinocytes against human
papilloma virus (HPV); therefore, severe cutaneous HPV
Figure 4 Omenn Syndrome in a Sardinian 5-month-old female
infant (absence of RAG1-RAG2 mutations, unidentified gene
defect). “Leaky” mutations of practically all SCID genes (whose null
mutations cause instead typical SCID) produce Omenn syndrome, in
fact described in infants with defects of RAG1-RAG2, DCLRE1C-
Artemis, ADA, DNA Ligasi IV, RMRP-CHH, common gc, IL7Ra, WHN-
FOXN1, ZAP-70, and complete DiGeorge anomaly (DiGeorge
Syndrome; CHARGE). In many infants with Omenn syndrome, that is
clinically not leaky but very serious, genetic defect remains
unidentified (several known, and probably also unknown, genes to
be sequenced).
Figure 5 David Vetter, the “Bubble Boy” (September 21, 1971 -
February 22, 1984). David Vetter, photograph reproduced with
kind permission of Prof. William T. Shearer, The David Center, Baylor
College of Medicine, Texas Children’s Hospital.
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frequent late complications in common gc( a n dJ A K 3 )
SCID patients many years after successful HSCT or
gene therapy [48].
In X-SCID fully HLA-matched sibling or family donor
HSCT without any conditioning is successful in > 95%,
however with frequent failure of donor B cell engraft-
ment [49]. By contrast, history of gene therapy in
X-SCID is very controversial [50].
JAK3 (Janus kinase 3) defect (OMIM 600802)
JAK3 defect is the AR T
-B
+NK
-SCID equivalent of the
common gc defect X-SCID, since that JAK3 joins to gc
in the [IL-2,4,7,9,15,21] - JAK3 - STAT5 signaling
pathway [47,51,52]. Most JAK3 SCID patients are com-
pound heterozygotes for two different mutations [5,51].
IL-7Ra (IL-7 receptor alpha chain) defect (OMIM 608971)
IL-7Ra defect is an AR T
-B
+NK
+ SCID because IL-15
function (—> NK cells) is normal and by contrast func-
tions of IL-7 and of TSLP (thymic stromal lymphopoie-
tin), that share the a c h a i ni nt h e i rr e c e p t o r s ,a r e
compromised [47,53,54]. In humans, IL-7 produced by
stromal cells of lymphoid tissues and by hepatocytes is
the true “T cell growth development factor” [55], and so
its dosage in Guthrie card eluate is a complementary
(respect to TRECs test) method for newborn SCID
screening: blood IL-7 is increased “by feedback” if low
Figure 6 Pediatric Research 1977, January. In January 1977, a special issue of Pediatric Research (cover) reported about David Vetter.
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indicate T
- SCID [56]; note that IL-7 levels may be nor-
mal in T
+ or T
++ SCID (e.g., massive engraftment of
maternal T lymphocytes, and Omenn syndrome; see
before), and therefore TRECs test appears to be the best
method for newborn SCID screening.
SCID caused by pre-T cell receptor defects
The pre-T cell receptor (pre-TCR), formed by a TCRb
chain (rearranged TCRb gene) and by the disulfide-
linked invariant pre-TCRa chain (pTa chain; codified
by the PTCRA gene, localized at 6p21.2, and really a
very suspect candidate gene for SCID) has an essential
role during T lymphopoiesis in thymic microambient at
the stage of large pre-T cell [57]. The pre-TCR also
transmits its signal through numerous other molecules
common to the TCR (T cell receptor of mature T lym-
phocytes): CD3 complex (CD3g,C D 3 δ,C D 3 ε,C D 3 ζ),
protein-tyrosine kinases (e.g., Fyn, Lck, ZAP-70), pro-
tein-phosphotyrosine phosphatases (CD45, and others),
etc. [58]
It is evident the similarity with the pre-B cell receptor
(pre-BCR) of B lymphopoiesis: defects of the pre-BCR
(Igμ, l/VpreB, Iga,I g b,B r u t o nt y r o s i n ek i n a s eB T K ,Bc e l l
linker protein BLNK) cause arrest of the development of B
lymphocytes at the stage of large pre-B cell and therefore
agammaglobulinemia [59]; defects of the pre-TCR, subdi-
vided into 1) defects of V(D)J recombination and 2) defects
of signaling through the pre-T cell receptor, cause arrest of
the development of T lymphocytes at the stage of large
pre-T cell and therefore SCID (Figure 7).
1) Defects of V(D)J recombination
The variable antigen-specific regions of the TCR b chain
of pre-TCR, Igμ chain of pre-BCR and then TCR, BCR
and Ig chains are encoded by the correspondent gene
domains rearranged through the V(D)J recombination of
DNA [60]. This recombination happens in two steps: 1
st
step specific to T and B lymphocytes (RAG1 and RAG2
“transposases”, encoded by the “Recombination Activat-
ing Genes” RAG1 and RAG2); and 2
nd step due to the
“Non-Homologous End-Joining” (NHEJ) proteins -
Ku70/80, DNA-PKcs, Artemis, Cernunnos/XLF, DNA
ligase IV, XRCC4 - pathway, that repairs double-strand
breaks in DNA in all living cells [61].
Defects of all these molecules cause T
-B
-NK
+ SCID
because, again, note that contrary to T and B lympho-
cytes NK cells do not rearrange their germline DNA to
produce genes encoding antigen-specific receptors. In
defects of 1
st step (RAG1, RAG2), abnormalities are lim-
ited to T and B lymphocytes; by contrast, defects of 2
nd
step (NHEJ) affect all cells and cause problems similar
to other syndromes with DNA repair defects: cellular
radiosensitivity, extreme toxicity by pre-HSCT condi-
tioning (especially by alkylating agents and, obviously,
by irradiation), predisposition to neoplasia, and (but
only in some forms: defect of DNA ligase IV, defect of
Figure 7 Pre-TCR and pre-BCR. Schematic drawing of pre-T cell receptor (pre-TCR; thymus, large pre-T cell with rearranged TCRb gene) and
pre-B cell receptor (pre-BCR; bone marrow, large pre-B cell with rearranged IgHμ gene). Defects of the pre-TCR, subdivided into defects of V(D)J
recombination and defects of signaling through the pre-T cell receptor, cause arrest of the development of T lymphocytes at the stage of large
pre-T cell and therefore SCID; defects of the pre-BCR cause arrest of the development of B lymphocytes at the stage of large pre-B cell and
therefore agammaglobulinemia.
Cossu Italian Journal of Pediatrics 2010, 36:76
http://www.ijponline.net/content/36/1/76
Page 8 of 17Cernunnos/XLF) dysmorphic facies, microcephaly, psy-
chomotor delay [62].
RAG1 or RAG2 defect (OMIM 601457) RAG1 or
RAG2 defect causes typical T
-B
-NK
+ SCID, Omenn syn-
drome, and also some rare peculiar forms: immunodefi-
ciency with early onset of multivisceral and recurrent
CMV infection, autoimmune cytopenia, restricted T cell
repertoire with TCRab
+ lymphopenia and markedly
expanded TCRgδ
+ T cells; immunodeficiency with
extensive granulomatous disease involving the skin,
mucous membranes and internal organs, and EBV-lym-
phoma; etc. [36,63]
In humans have been identified radiosensitive T
-B
-NK
+ SCID due to defects of four NHEJ molecules:
Artemis defect (OMIM 602450) Artemis defect, due to
mutations of the DCLRE1C (DNA cross-link repair pro-
tein 1C) gene, is present with various mutations in all
world populations; once it was known as “SCIDA”, that
is SCID of Athabascan-speaking Native Americans
(Apache, Navajo), in which because of a founder effect 1
person every 10 is heterozygote for the mutation exon 8
C576A Artemis Y192X and 1 in 2,000 newborn is
affected [64].
DNA ligase IV defect (OMIM 606593) DNA ligase IV
defect causes the “Ligase IV syndrome” (phenotypically
similar to the Nijmegen breakage syndrome, NBS) with
possible typical SCID or Omenn syndrome, dysmorphic
facies, microcephaly, growth retardation, psychomotor
delay, skin anomalies, pancytopenia, and predisposition
(also in heterozygotes) to leukemia and other neoplasia [65].
Cernunnos/XLF defect (OMIM 611291) Cernunnos/
XLF defect causes combined immunodeficiency (usually
manifested later respect to typical SCID) with short sta-
ture, multiple dysmorphisms, microcephaly, psychomo-
tor delay, bone marrow failure and myelodysplasia [66].
DNA-PKcs defect Recently in a girl from consangui-
neous parents of Turkish origin, diagnosed with AR T
-
B
-NK
+ SCID when she was 5-month-old, has been iden-
tified the first human case of DNA-PKcs (DNA-depen-
dent Protein Kinase catalytic subunit) defect, due to a
homozygous missense mutation (T9185C L3062R) of
the coding gene PRKDC (OMIM 600899). It was known
since many years that mutations of PRKDC (Protein
kinase, DNA-activated, catalytic polypeptide) gene cause
the naturally occurring SCID in mice, Arabian foals and
Jack Russell terriers; so, DNA-PKcs defect has been long
predicted in human SCID and finally found. Note that
the PRKDC gene includes 86 exons (very cumbersome
sequencing), and that the expression of DNA-PKcs pro-
tein, composed by 4096 aminoacids, can be normal but
with defect of function [67].
HSCT is particularly problematic in all SCID caused
by defects of V(D)J recombination, especially if radiosen-
sitive (see later).
2) Defects of signaling through the pre-T cell receptor
CD3δ,C D 3 ε,C D 3 ζ or CD3g defect (OMIM 608971;
608971; 610163; 186830) Complete CD3δ, CD3ε, CD3ζ
or CD3g defect can cause AR T
-B
+NK
+ SCID (about 1%
of SCID): the different CD3 subunits, organized as gε, δε
and ζζ dimers, join to pre-TCR and then TCR and are
essential for their assemblage in cell membrane and sig-
nal transmission and therefore thymic T lymphopoiesis
and mature T lymphocyte activation; defects cause dif-
ferently severe phenotypes [68,69].
CD45 defect (OMIM 608971) Very rare is also the AR
T
-B
+NK
+/- SCID caused by CD45 defect [70]: CD45
(LCA, Leucocyte Common Antigen) is a protein-phos-
photyrosine phosphatase essential for pre-TCR and TCR
(and BCR also) signaling, constitutes about 10% of the
proteins of T and B lymphocyte membrane, and exists
in multiple isoforms produced by complex alternative
splicing of the exons encoding its extracellular domains.
The expression of the different CD45 isoforms depends
on cell type and state of differentiation and activation
(e.g., naïve CD4
+CD45RA
+ T cells, and memory CD4
+CD45RO
+ T cells); it is also very interesting the asso-
ciation between CD45 polymorphisms and susceptibility
or resistance to infective or autoimmune diseases [71].
ZAP-70 defect (OMIM 176947) ZAP-70 defect causes a
characteristic deficiency of CD8
+ T lymphocytes, mani-
fested as AR T
+ (CD4
+CD8
-)B
+NK
+ SCID or as less
severe phenotypes [16,72].
p56lck defect As i n g l ec a s eo fA RT
-B
+NK
+ SCID
caused by p56lck defect has been reported (not identi-
fied mutation, but aberrant splicing with exon 7 absence
in the transcribed mRNA and very reduced protein
expression) [73]; p56lck (OMIM 153390) defective activ-
ity has been also observed in adults with idiopathic CD4
lymphopenia [74].
SCID caused by increased lymphocyte apoptosis
Reticular dysgenesis (RD) (OMIM 267500)
Reticular dysgenesis associates AR T
-B
-NK
- SCID and
severe congenital neutropenia (arrest of myeloid matura-
tion at the promyelocyte stage) with total leukocytes
< 400/μL ("aleukocytosis”), fatal neonatal sepsis, no
response to granulocyte colony-stimulating factor (G-
CSF), and severe sensorineural deafness in babies surviv-
ing after successful HSCT. RD is caused by mutations
(missense mutations; deletions) of the AK2 gene, encod-
ing the mitochondrial enzyme adenylate kinase 2 (AK2)
[75,76]. Adenylate kinases (AK) catalyze the reversible
transfer of a phosphoryl group from adenosine tripho-
sphate to adenosine monophosphate: 2 ADPs < == >
ATP + AMP; from bacteria to humans, every cell sur-
vives only if ATP/ADP/AMP concentrations maintained
within very narrow and tightly regulated ranges [77].
Seven different AK isozymes exist in human cells, with
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sol) and AK2-AK3-AK4 (mitochondrial) are present in
all cells except for blood nucleated cells and cells of stria
vascularis in the inner ear, that express only AK2.A K 2
is located in the mitochondrial intermembrane space,
the same as HAX-1 whose defect causes Severe Conge-
nital Neutropenia of the families originally described by
Kostmann [78].
Adenosine deaminase deficiency (ADA-SCID) (OMIM 102700)
The purine salvage enzyme adenosine deaminase (ADA)
catalyzes the irreversible deamination of adenosine
(Ado) and 2-deoxyadenosine (dAdo) to inosine and to
deoxyinosine, respectively, and its deficiency results in
“metabolic poisoning“ from accumulation of Ado, dAdo
and deoxyadenosine triphosphate (dATP). Excess intra-
cellular dAdo and dATP cause generalized lymphocyte
apoptosis (—>T
-B
-NK
- SCID), while excess extracellular
Ado (normally produced by CD4
+ TReg lymphocytes)
acts on specific receptors with further lymphocyte inhi-
bition [79] and might be important for frequent mani-
festations of immune dysregulation and autoimmunity
(type I diabetes, hypothyroidism, autoimmune thrombo-
cytopenia, hemolytic anemia) also reported in ADA-
SCID patients treated by HSCT or gene therapy [80]. In
humans the highest ADA enzyme activity is found in
lymphocytes, particularly in intrathymic immature T
cells, but ADA is an ubiquitous “housekeeping” enzyme
present in all cell types; therefore, ADA deficiency is a
‘systemic’ metabolic disorder causing SCID as well as
several nonimmunological abnormalities: alterations of
the ribs (costochondral junctions), vertebral bodies, iliac
crests and other skeletal segments [81]; neonatal hepati-
tis; renal and lung abnormalities; sensorineural deafness;
neurological anomalies (cognitive, motor and behavioral
problems) with a poor prognosis also after the correc-
tion of the immune defect [82]. IQ < -2 SD correlates
with dATP levels at diagnosis; also note that the isolated
genetic deficiency of the enzyme S-adenosyl homocys-
teine hydrolase (SAHH), inhibited by Ado, causes severe
psychomotor delay [83].
Really, different therapeutic options exist for the treat-
ment of ADA-SCID [84,85]:
- fully HLA-matched sibling or family donor HSCT
without any conditioning is the treatment of choice,
with success > 90%; at present, data from matched
unrelated donor HSCT are not conclusive; by con-
trast, mismatched HSC transplants (parental haploi-
dentical donor; mismatched unrelated donor), both
without conditioning and with myeloablative or
reduced-intensity conditioning, have poor chance of
success and should be avoided;
- enzyme replacement therapy (ERT): weekly or
twice-weekly intramuscular injection of PEG-ADA
(polyethylene-glycol-modified calf intestinal ADA)
protects from “metabolic poisoning” both lympho-
cytes (restoring immune function within 2 to 4
months) and other cells, and it is often life-saving
therapy at diagnosis; ERT gives an overall 80% prob-
ability of surviving at 20 years; in the remaining 20%
of patients, early mortality (within 6 months) results
from serious conditions already present at diagnosis,
late mortality from refractory hemolytic anemia,
chronic respiratory insufficiency, lymphoproliferative
disorders, liver malignancies; note that long-term (8-
10 years) PEG-ADA treated patients show a gradual
decline of thymic function and T cell counts;
- autologous HSC gene therapy (GT): as described
recently [85,86], gene therapy had in ADA-SCID
patients the most promising results.
Purine nucleoside phosphorylase (PNP) deficiency (OMIM
613179)
Purine nucleoside phosphorylase (PNP) follows ADA in
the purine salvage pathway, and PNP deficiency also
causes SCID (excess deoxyguanosine and deoxyguano-
sine triphosphate cause apoptosis of lymphocytes,
mainly immature T lymphocytes). Note that PNP defi-
cient cells do not produce uric acid, and therefore low
uric acid in serum (< 2 mg/dL, usually < 1 mg/dL) sup-
ports the diagnosis. PNP deficiency has a poor prognosis
[87]: PEG-PNP is not commercialized, and gene therapy
is still experimental in mice; HSCT is the only therapy,
but it does not correct the severe neurological problems
usually present (hypertonia, hypotonia, ataxia, psycho-
motor delay); autoimmunity (hemolytic anemia, autoim-
mune thrombocytopenia, neutropenia, arthritis, etc.) and
neoplasia are also frequent.
SCID caused by defects in thymus embryogenesis
Thymocytes cannot develop to normal mature T lym-
phocytes without cross-talk with thymic cells (thymic
epithelial cells, TECs; thymic stromal cells; thymic
medullary dendritic cells) [88,89]; two forms of SCID
recognize a primary embryonic thymic defect:
Nude/SCID Syndrome (OMIM 601705)
The gene WHN (wingled helix naked) encodes the
FOXN1 (forkhead box N 1) transcription factor selec-
tively expressed in thymic epithelia and skin, and its
mutations cause the mouse Nude/SCID phenotype and
also the equivalent human Nude/SCID syndrome (con-
genital total alopecia, and absence of the thymus with
AR T
-B
+NK
+ SCID) [29,90]. The human form has been
first identified in two sisters of a small Italian village,
Acerno, where because of a founder effect the 6.52% of
inhabitants are heterozygous carriers of the mutation
exon 5 C792T R255X [91]. FOXN1 appears also essen-
tial for the embryonic development of the neural tube:
an affected fetus, with absence of thymus and abnormal
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the village there is a high rate of abortions in the first
trimester in the marriages between heterozygous for the
FOXN1 mutation [92].
Complete DiGeorge anomaly
Complete DiGeorge anomaly, characterized by absence
of the thymus with consequent T
-B
+NK
+ SCID and var-
iously associated facial dismorphy, congenital heart dis-
ease (conotruncal malformations), and neonatal
hypocalcemia by defect of parathyroid glands, has differ-
ent etiologies [93]:
- approximately 50%: DiGeorge Syndrome (OMIM
188400) [94] by 22q11.2 deletion of about 3 Mb
i n t e r e s t i n g>3 5g e n e s ,a m o n gw h i c ht h eTBX-1 (T-
box 1) gene involved in the development of heart,
thymus, parathyroid glands, palate, face; note that
the vast majority of infants with DiGeorge syndrome
have “partial” DiGeorge anomaly, with low T cell
counts but not the immunodeficiency of complete
DiGeorge anomaly;
- about 25%: CHARGE association (coloboma, heart
defects, atresia choanae, retardated growth and
development, genital hypoplasia, ear anomalies/deaf-
ness; OMIM 214800), with in the majority of
patients mutation of the CHD7 gene, encoding the
chromodomain helicase DNA-binding protein-7
[95,96];
- about 15%: diabetic mother embryopathy [97].
22q11.2 deletion and CHD7 mutation have autosomal
dominant transmission, with de novo mutation in more
than 80% of cases; in around 1/3 of the cases, SCID
manifests as Omenn syndrome ("atypical” complete
DiGeorge anomaly).
These children have normal hematopoietic stem cells
that cannot develop to mature T lymphocytes because of
the absence of thymic stroma and epithelium; so, the spe-
cific treatment of thymic aplasia is thymus transplant:
neonatal thymus took during newborn heart surgery and
cultured in vitro to eliminate the HLA not-matched thy-
mocytes, and then insertion of multiple slides containing
thymic epithelium (that is, surprisingly, functionally not
HLA-restricted) into the quadriceps muscle of the SCID
infant [98]. However, thymus transplant is a technically
very demanding procedure, and there is only one center
in the United States (Duke University Medical Center,
Durham, NC 27710, USA) that is currently able to
accomplish it [99]. Alternatively, a satisfactory T cell
immunity may also be obtained in these children by the
adoptive transfer of HLA identical expanding and long-
lasting T lymphocytes present in simple peripheral blood
mononuclear cells (PBMC), bone marrow, or cord blood
of a fully HLA-matched donor [100].
SCID caused by impaired calcium flux
ORAI1 defect-STIM defect
The variations of intracellular Ca
2+ levels are a funda-
mental mechanism for the signal transduction in all liv-
ing cells [101]. In T lymphocytes, the activation of the
TCR/CD3 complex causes a release of intracellular Ca
2+
from the endoplasmic reticulum (ER) stores, followed by
a “store operated Ca
2+ entry” (SOCE) that is a conspicuous
influx into the cell of other Ca
2+ ions from extracellular
space because of opening of the Ca
2+ release-activated cal-
cium channels (CRAC) of the cell membrane; a main final
effect of intracellular Ca
2+ increase is translocation of
NFAT (nuclear factor of activated T cells) into the
nucleus, with activation of specific genes.
In rare AR T
+B
+NK
+ SCID patients has been identi-
fied a SOCE-CRAC defect, caused by mutations in
genes encoding two highly conserved proteins: ORAI1
(subunit forming pores in CRAC; its name comes from
ORAI, the three sisters of Greek mythology), and
STIM1 (stromal interaction molecule-1; it is the sensor
of Ca
2+ levels in ER and the activator of ORAI1-CRAC).
The clinical phenotypes of the ORAI1 defect (OMIM
612782) and of the STIM defect (OMIM 612783) are
similar [15]: serious AR T
+B
+NK
+ SCID, with normal T,
B and NK cell differentiation and counts but severe T
lymphocyte defect of Ca
2+ influx and of proliferation
after mitogen stimulation, ipergammaglobulinemia but
with deficiency of specific antibody production, congeni-
tal non-progressive global myopathy (hypotonic infant),
ectodermal dysplasia (anhydrosis, defects in the forma-
tion of dental enamel). In the STIM1 defect there is also
CD4
+ TReg lymphocyte deficiency, with severe autoim-
munity (autoimmune thrombocytopenia, hemolytic ane-
mia), enlarged lymph nodes and epatosplenomegaly.
SCID caused by other mechanisms
Coronin-1A defect
Mice with a homozygous missense mutation in the Cor-
onin-1A (CORO1A) gene show severe T cell lymphope-
nia; this has suggested the recent discovery of the
absence of Coronin-1A in a 13-month-old girl with AR
T
-B
+NK
+ SCID, by deletion of the entire CORO1A gene
on one allele (600 kbs deletion in 16p11.2) and a dinu-
cleotide deletion resulting in frameshift and premature
termination on the other allele [102,103]. Coronins (1A,
1B, 1C, 2A, 2B, 7) are a highly conserved family of pro-
teins, regulators of cell F-actin structures, cytoskeletal
rearrangements and intracellular membrane transport;
they, by contrast to WASP (Wiskott-Aldrich Syndrome
Protein) antagonize actin polymerization. Coronin-1A
(OMIM 605000) is especially expressed in T cells, and
its defect causes an excess of F-actinin in the cortex thy-
mocytes with drastically impaired cell movement,
intrathymic retention of single positive CD4
+CD8
- or
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-CD8
+ mature T lymphocytes, and severe peripheral
T lymphopenia [104].
MHC Class II (MHCII) defect (OMIM 209920)
The genes CIITA, RFXANK, RFX5, RFXAP encode four
factors that regulate promoters and transcription of the
HLA DR, DP, DQ cluster, localized at 6p21.3; their
mutations cause absence of Major histocompatibility
complex class II (MHCII) molecules, normally expressed
at cell surface by thymic epithelial cells, activated T lym-
phocytes, and cells (B lymphocytes, dendritic cells,
monocytes/macrophages) that present antigens to CD4
+
T lymphocytes. Apart from a minority of “attenuated”
cases, typical MHC class II deficiency causes a serious
AR T
+ (CD4
-CD8
+)B
+NK
+ SCID with a poor prognosis
and overall cure rate < 50% also by HSCT from familial
HLA-matched donor. HSCT in these patients is compli-
cated by a high incidence of acute GvHD associated
with preexisting viral infections, and it is highly recom-
mended that HSCT be performed in young children (<
2 years), using either an HLA-identical sibling or the
best available compatible donor [105].
CHH (Cartilage hair hypoplasia) (OMIM 250250)
Mutations of the highly polymorphic RMRP (ribonu-
clease mitochondrial RNA processing) gene, encoding
not a protein but the 267-nucleotide-long RNA compo-
nent of the mitochondrial RNA-processing endonuclease
(a multiprotein RNA complex with at least ten different
proteins) cause defects in ribosomal RNA processing and
mitochondrial and cellular replication, and a heteroge-
neous phenotypic spectrum [37]. Cartilage hair hypopla-
sia, particularly frequent in the Amish and the Finnish
populations (respectively 1:19 and 1:76 individuals car-
riers of the mutation g.70 A > G, because of a founder
effect) is a metaphyseal chondrodysplasia with short-
limbed dwarfism, light-colored hypoplastic hair, and vari-
able immunodeficiency: AR T
-B
+NK
+ SCID (also mani-
fested as Omenn syndrome), selective CD8
+ T
lymphopenia, or even not relevant immunologic defects;
patients with combined immunodeficiency without skele-
tal alterations have also been reported. Apart from CHH,
mutations of RMRP (usually in different nucleotides of
the RNA molecule) cause other three skeletal disorders:
metaphyseal dysplasia without hypotrichosis (MDWH),
kyphomelic dysplasia, and anauxetic dysplasia.
Hoyeraal-Hreidarsson Syndrome (HHS) (OMIM 300240)
Hoyeraal-Hreidarsson syndrome (HHS), characterized by
telomerase defect and by the pathognomonic association
of T
+B
-NK
- SCID and cerebellar hypoplasia (Figure 8), is
the severe infantile variant of dyskeratosis congenita
[17,106]. Defective telomerase activity affects all tissues
in constant renewal (bone marrow, skin, oral and gut
epithelium, lung alveolar epithelium, etc.) and also devel-
opment, differentiation and activation of lymphocytes; it
also causes extreme toxicity by pre-HSCT conditioning
(especially by alkylating agents and by irradiation), similar
to defects of NHEJ.
XL-HHS and the “classical” X-linked dyskeratosis con-
g e n i t a( X L - D C )a f f e c to n l ym a l e sa n da r ed u et om u t a -
tions of the DKC1 gene within Xq28, encoding dyskerin,
a component of telomerase [17]. Various other genetic
defects cause HHS both in male and female infants: AR-
HHS by homozygous mutations of the TERT gene
encoding telomerase reverse-transcriptase [107]; AD-
HHS by heterozygous mutations of the TINF2 gene
encoding TIN2 (TRF1-interacting nuclear protein 2),
one of the components (six proteins) of the shelterin
telomere protection complex [108,109]; and AD-HHS by
heterozygous mutation of DCLRE1B (DNA cross-link
repair protein 1B) gene, encoding Apollo, a DNA repair
factor interacting with the shelterin complex (mutation
recently identified by Revy et al. in the HHS female
infant described by them ten years ago) [110,111].
Hereditary folate malabsorption (HFM) (OMIM 229050)
Hereditary folate malabsorption (HFM) is due to pro-
ton-coupled folate transporter (PCFT) gene mutations
and consequent folate malabsorption in the duodenum
and upper jejunum, with depletion of transplacentally
acquired stores at 3-4 months of age; PCFT also trans-
ports folate through choroid plexus into the cerebrosp-
inal fluid. Lymphocytes and developing nervous system
are particularly sensitive to the defective thymidine
Figure 8 Hoyeraal-Hreidarsson Syndrome. Cerebellar hypoplasia
in a Sardinian 6-month-old male with T
+B
-NK
- SCID; missense
mutation of DKC1 gene encoding dyskerin (X-linked Hoyeraal-
Hreidarsson syndrome).
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deficiency. Affected infants show failure to thrive, diar-
rhea, anemia (megaloblastic, but masked to normocytic
if associated iron deficiency), infections, hypogammaglo-
bulinemia and an AR T
+B
+NK
+ SCID phenotype; they
also present seizures and, if not treated promptly, severe
neurodevelopmental defects. Serum and cerebrospinal
fluid folate levels are undetectable.
This is a special reversible SCID: parenteral folate
repletion causes a dramatic recovery of immunodefi-
ciency and, if prompt and aggressive, prevents irreversi-
ble neurological damages [112].
Hematopoietic stem cell transplantation (HSCT)
SCID can be successfully treated by HSCT, the only
curative option for most affected infants; several recent
papers [113-116] report on survival and long-term out-
come in several hundreds of patients over the last dec-
ades, with a success rate ranging from 70-95 percent
and varying incidence of adverse effects and
complications.
Main variables influence the outcome of HSCT [117]:
￿ Age and clinical condition at the time of diag-
nosis and of HSCT: there is an always increasing
evidence of best outcome if diagnosis and HSCT
performed in the first few months of life (1-4
months), before clinical presentation with infections
and failure to thrive; of course, this underlines the
importance of population-based newborn screening
for SCID, that permits the early diagnosis of asymp-
tomatic newborns.
￿ HSC donor: unfortunately, only a minority of
SCID infants have an HLA-matched sibling,
obviously the ideal donor; for infants without a
matched related donor, alternative donors are an
HLA-matched unrelated volunteer or an HLA-
matched unrelated banked cord blood unit, or, if
none of these is available in a very short time, rigor-
ously T-depleted haploidentical related (mother or
father) bone marrow or peripheral blood stem cells
(PBSC).
￿ No conditioning versus conditioning regimen,
and SCID genotype/phenotype: HSCT engraftment
without any pretransplant conditioning regimen is
theoretically possible in most SCID infants, espe-
cially if NK
- SCID (e.g., ADA-SCID, common gc
defect, JAK3 defect), but with frequently defective
donor B cell reconstitution and so persistent B cell
deficiency that requires long-term (for the rest of
life) immunoglobulin replacement therapy. New,
now in use, cytoreductive nonmyeloablative regi-
mens, particularly those including fludarabine,
appear safe and causing a reduced toxicity and
presumably reduced long-term effects on for exam-
ple growth and endocrine system: therefore they are
probably recommended, if possible, also in all these
very young (few months of age) children [118].
In SCID infants with V(D)J recombination - DNA
repair defects (especially NHEJ defects) the molecu-
lar problem causes cellular radiosensitivity and
extreme toxicity by “historical” pretransplant condi-
tioning regimen (especially by alkylating agents and,
obviously, by irradiation); the same is true in
patients with telomerase defect (Hoyeraal-Hreidars-
son syndrome and also its “later” form, classical dys-
keratosis congenita).
Not only because of the different sensitivity to condi-
tioning regimen, SCID genotype/phenotype influence
the outcome of HSCT: e.g., a better outcome is usual in
SCID with common gc or JAK3 defect (a part from fre-
quent cutaneous HPV) and IL-7Ra defect; on the con-
trary, a complicated outcome is more frequent in SCID
with V(D)J recombination - DNA repair defects (high
risk of conditioning toxicity, obviously if not “disease-
specific” strategy for nonmyeloablative regimen; and,
also if normal immunologic reconstitution, frequent
autoimmunity, gut problems, etc.) and in ADA-SCID
(frequent neurological anomalies: cognitive, motor and
behaviour problems) with a poor prognosis also after
the correction of the immune defect.
Gene Therapy (GT)
Gene therapy, i.e., the insertion of normal gene through
a vector virus (e.g., defective Moloney murine leukemia
virus, M-MLV) into DNA of autologous CD34
+ hemato-
poietic stem cells, progenitors also of lymphocytes, had
practical application in two forms of SCID with different
results [50,86,119,120].
￿ B e g i n n i n gi n1 9 9 9i nP a r i sa n di n2 0 0 1i nL o n d o n
two European groups performed gene therapy for
treating common gc defect XL-SCID in respectively
11 and 10 children, aged from 1 to 33 months; 17 of
21 children had satisfactory T cell reconstitution,
and 12 of them had also normal B cell reconstitution
with no more need for immunoglobulin replacement
therapy. Unfortunately, 5 children (4 in Paris, 1 in
London) at 24-68 months from gene therapy devel-
oped an acute lymphoblastic leukemia (ALL) mainly
because complex mutagenesis started with the inser-
tion at 11p13 of a single copy of the defective retro-
virus, containing the normal IL2RG gene but also its
enhancer, near the promoter of LMO2 (LIM domain
only 2), known oncogene of T lymphocytes then
aberrantly transcribed and expressed (insertional
mutagenesis) [121,122]. One child was dead from
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the occurrence of this serious complication led to
stop of gene therapy for common gc defect XL-SCID
in Europe. In the United States a gene therapy trial,
now closed for new patients, recluted 8 patients
already treated unsuccessfully with allogeneic HSCT:
in the first 3 patients (aged 10-14 years), immunolo-
gical recovery has been poor, probably due to age-
related thymic involution and chronic viral
infections.
￿ Gene therapy had very good results in ADA-SCID
children, and it is really indicated in ADA-SCID
patients without an HLA-matched related donor, as
particularly described in the 15 patients (age at GT
6m o n t h s-5 . 6y e a r s )o ft h ec a s i s t i co fA i u t iet al.
[86]. Aiuti used an ameliorated transduction proto-
col of CD34
+ autologous stem cells by a defective
MLV vector, nonmyeloablative conditioning (busul-
fan 2 mg/kg ev at days -3 and -2) to create space in
the bone marrow, and stopping of PEG-ADA treat-
ment to give a selective proliferative vantage to lym-
phocytes with corrected gene. All 15 patients are
alive, with in the first 10 treated patients: good
immunological recovery in 9/10, persistent expres-
sion of ADA with “systemic detoxification” without
any more need for PEG-ADA until 8 years since
gene therapy in 8/10, and no more need for immu-
noglobulin replacement therapy in 5/10. Similar
results have been reported in patients treated by
other groups. Especially, in no patient has been
reported the complication of the clonal leukemic
proliferation because of insertional mutagenesis, and
this also if the viral vector however inserts itself dan-
gerously in proximity of LMO2 or other known
oncogenes.
There is now an intense research for different viral
vectors that do not present problems of insertional
mutagenesis: SIN (self-inactivating) Lentiviruses inte-
grate also in the cells not in mitosis, and (on the con-
trary of gammaretrovirus such as MLV) do not have as
preferential integration site the promoter regions of
active (expressed) genes [123]. The recent report of a
clonal expansion from integration of Lentivirus vector in
the DNA-binding protein HMGA2 (high mobility group
AT-hook 2) gene in a patient of the gene therapy trial
for thalassemia in France [124] imposes however further
caution.
Conclusions
More than thirty identified genetic defects cause human
SCID and certainly novel genes and molecular mechan-
isms will be discovered over the next few years, maybe
between function-based candidate genes (e.g., PTCRA
gene encoding the invariant pre-TCRa chain; genes
encoding scaffold proteins involved in immune signal-
ing; genes encoding DNA repair proteins).
Human SCID is always a prenatal disorder of T lym-
phocyte development: it is already present at birth even
if clinically silent in most affected newborns, therefore
the universal newborn screening for SCID (as started in
Wisconsin) is really of great practical importance. If not
identified at birth, SCID manifests itself in the first few
months of life as typical lymphopenic T
- SCID or atypi-
cal T
+/T
++ SCID (especially Omenn syndrome), but
always as a pediatric emergency. Essentially every
affected infant could be cured by very early diagnosis,
prompt prevention (sterile rooms!) and treatment of
infections, and timely hematopoietic stem cell transplan-
tation (or, if ADA deficiency, gene therapy or enzyme
replacement therapy). Knowledge of the different genetic
and clinical forms of SCID is essential for the most
accurate approach to diagnosis and treatment as well to
family counseling.
Consent
Written informed consent was obtained from the par-
ents of the infants for publication of images and clinical
data in Figure 3, Figure 4 and Figure 8. A copy of the
written consent is available for review by the Editor-in-
Chief of this journal.
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